For decades, the medical community has treated Alzheimer’s, Parkinson’s, and ALS as distinct silos—separate tragedies with separate causes. But a growing body of evidence suggests that these conditions may not be isolated illnesses at all. Instead, they appear to be a complex web of overlapping brain disorders, sharing biological roots that scientists are only now beginning to untangle.
This paradigm shift toward identifying shared mechanisms in neurodegenerative diseases was the central theme of the 13th annual Helen and Robert Appel Alzheimer’s Disease Research Institute Symposium. Held at Weill Cornell Medicine, the gathering brought together clinicians and researchers to discuss a fundamental change in strategy: moving away from the search for a single “silver bullet” protein and instead widening the lens to find the common threads that link various forms of dementia and motor neuron disease.
The goal is to move “upstream” of the damage. Rather than simply treating the protein clumps that appear in the brain during the late stages of disease, researchers are hunting for the primary triggers—the genetic modifiers and cellular malfunctions—that allow those clumps to form in the first place.
“The vision of the Appel Institute is simple. We wanted to tackle some of the most devastating diseases: Alzheimer’s, Parkinson’s, ALS, frontotemporal dementia and some rare neurological disorders,” said Dr. Li Gan, director of the Institute at Weill Cornell Medicine.
Genetic Modifiers: Why Some People Stay Healthy
One of the most promising avenues in this new research focuses on the GBA gene. Mutations in GBA have long been linked to Gaucher’s disease, but they are similarly significant risk factors for Parkinson’s disease and dementia with Lewy bodies. But, the presence of a mutation does not always guarantee a diagnosis.
Dr. Sreeganga Chandra, a professor of neurology and neuroscience at Yale University, is investigating why some individuals with GBA mutations never develop symptoms, even when they inherit two copies of the mutated gene. This suggests the existence of “modifier genes” that can either protect the brain or accelerate its decline.
Dr. Chandra’s team is specifically looking at a gene called GANC. Their research indicates that GANC may influence the aggregation of $alpha$-synuclein, a protein that misfolds into “Lewy bodies”—the hallmark of both Parkinson’s and Lewy body dementia. When GANC activity is increased, $alpha$-synuclein aggregation decreases; when it is decreased, the aggregation increases.
“We are proposing that GANC is an actual modifier of GBA-linked Parkinson’s disease,” Dr. Chandra said. As this gene is mutated in a significant portion of the Caucasian population, it may play a critical role in how the disease manifests across different demographics.
Beyond the Neuron: The Role of Support Cells
Historically, neurodegenerative research focused almost exclusively on neurons—the electrically active cells that transmit signals. However, the focus is now shifting toward non-neuronal cells, particularly astrocytes. These star-shaped cells provide the essential infrastructure of the brain, offering nutrients, insulation (myelin), and immune defense.
Dr. Anna Orr, an associate professor at Weill Cornell, is exploring how these support cells can actually drive cognitive decline. Her research focuses on the protein TDP-43, which is common in frontotemporal dementia (FTD), ALS, and Alzheimer’s. When TDP-43 malfunctions, astrocytes can release chemokines—signaling molecules that trigger inflammation.
This inflammation causes healthy neurons to misfire or “over-fire,” creating a toxic environment. Dr. Orr’s team discovered that removing the chemokine gene improved cognitive performance in models, leading her to conclude that the activity of these affected astrocytes was “sufficient to cause progressive cognitive decline.”
Dr. Orr is investigating the overproduction of free radicals within astrocytes. By blocking the specific sites where these radicals are released, her lab has been able to lower inflammation and protect neurons. This discovery has led to the development of potential therapeutic compounds designed to stop oxidative harm and potentially reverse the course of certain dementias.
Finding the Root Cause Upstream
To illustrate the need for this shift in perspective, Dr. Edward Lee, director of the Center for Neurodegenerative Disease Research at the University of Pennsylvania, used a vivid analogy: imagine people standing by a river, frantically saving babies from drowning, while one person walks upstream to find out who is tossing the infants into the water.
In this analogy, the “babies” are the protein aggregates like amyloid or tau that doctors see during autopsies. For too long, research has focused on saving the babies (clearing the proteins) rather than finding the person upstream (the root cause).
Dr. Lee’s lab is investigating the VCP gene, which acts as a cellular “trash collector,” helping to degrade proteins tagged for disposal. When the VCP gene is mutated, the cell cannot clear out protein clumps, leading to “tauopathy”—a buildup of tau proteins. In one tragic case, Dr. Lee noted a family where a husband and three children all passed away from an inherited form of dementia linked to VCP mutations, despite the absence of traditional amyloid plaques.
This suggests that activating VCP could serve as a broad-spectrum therapeutic. Rather than targeting one specific protein, a VCP-based treatment could, in theory, target any ubiquitinated protein aggregate, regardless of whether the patient has Alzheimer’s or another form of dementia.
Comparison of Shared Biological Targets
| Biological Target | Associated Diseases | Role in Pathology |
|---|---|---|
| GBA/GANC Genes | Parkinson’s, Lewy Body Dementia | Modifiers of $alpha$-synuclein aggregation |
| Astrocytes | FTD, Alzheimer’s, ALS | Drivers of inflammation via chemokines |
| TDP-43 Protein | ALS, FTD, Alzheimer’s | Disruption of RNA splicing and protein making |
| VCP Gene | Inherited Dementias, Tauopathies | Failure of protein degradation/clearance |
As the field moves forward, the focus is shifting toward early detection and preventative intervention. This includes increased genetic screening for GBA mutations in Parkinson’s patients and a deeper investigation into pathogens that may trigger neurodegeneration early in life.
Disclaimer: This article is for informational purposes only and does not constitute medical advice. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.
The next phase of this research will involve clinical trials for the compounds currently being developed in the Orr lab and further genomic mapping to identify other modifiers similar to GANC. These efforts represent a move toward a future where neurodegenerative diseases are caught and stopped before the first symptom ever appears.
Do you or a loved one have experience with these conditions? We invite you to share your thoughts and questions in the comments below.
